151 related articles for article (PubMed ID: 27150054)
41. CDC6, a key replication licensing factor, is overexpressed and confers poor prognosis in diffuse large B-cell lymphoma.
Shen M; Zhang Y; Tang L; Fu Q; Zhang J; Xu Y; Zeng H; Li Y
BMC Cancer; 2023 Oct; 23(1):978. PubMed ID: 37833632
[TBL] [Abstract][Full Text] [Related]
42. Y-box-binding protein-1 (YB-1) promotes cell proliferation, adhesion and drug resistance in diffuse large B-cell lymphoma.
Miao X; Wu Y; Wang Y; Zhu X; Yin H; He Y; Li C; Liu Y; Lu X; Chen Y; Shen R; Xu X; He S
Exp Cell Res; 2016 Aug; 346(2):157-66. PubMed ID: 27397581
[TBL] [Abstract][Full Text] [Related]
43. [Ibrutinib inhibits mesenchymal stem cells-mediated drug resistance in diffuse large B-cell lymphoma].
Wu L; Zhang YZ; Xia B; Li XW; Yuan T; Tian C; Zhao HF; Yu Y; Sotomayor E
Zhonghua Xue Ye Xue Za Zhi; 2017 Dec; 38(12):1036-1042. PubMed ID: 29365396
[No Abstract] [Full Text] [Related]
44. NFYB potentiates STK33 activation to promote cisplatin resistance in diffuse large B-cell lymphoma.
Feng L; Xu X; Zhao K
Leuk Res; 2021 Dec; 111():106708. PubMed ID: 34536775
[TBL] [Abstract][Full Text] [Related]
45. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227
[TBL] [Abstract][Full Text] [Related]
46. A novel inhibitor of focal adhesion signaling induces caspase-independent cell death in diffuse large B-cell lymphoma.
Bosch R; Dieguez-Gonzalez R; Céspedes MV; Parreño M; Pavón MÁ; Grañena A; Sierra J; Mangues R; Casanova I
Blood; 2011 Oct; 118(16):4411-20. PubMed ID: 21868575
[TBL] [Abstract][Full Text] [Related]
47. Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells.
Dong L; Lv H; Li W; Song Z; Li L; Zhou S; Qiu L; Qian Z; Liu X; Feng L; Meng B; Fu K; Wang X; Pan-Hammarström Q; Wang P; Wang X; Zhang H
Oncotarget; 2016 May; 7(22):33350-62. PubMed ID: 27147575
[TBL] [Abstract][Full Text] [Related]
48. Long noncoding RNA HULC predicts poor clinical outcome and represents pro-oncogenic activity in diffuse large B-cell lymphoma.
Peng W; Wu J; Feng J
Biomed Pharmacother; 2016 Apr; 79():188-93. PubMed ID: 27044827
[TBL] [Abstract][Full Text] [Related]
49. The rGel/BLyS fusion toxin inhibits STAT3 signaling via down-regulation of interleukin-6 receptor in diffuse large B-cell lymphoma.
Lyu MA; Sung B; Cheung LH; Marks JW; Aggarwal BB; Aguiar RC; Rosenblum MG
Biochem Pharmacol; 2010 Nov; 80(9):1335-42. PubMed ID: 20654581
[TBL] [Abstract][Full Text] [Related]
50. A cytoplasmic ATM-TRAF6-cIAP1 module links nuclear DNA damage signaling to ubiquitin-mediated NF-κB activation.
Hinz M; Stilmann M; Arslan SÇ; Khanna KK; Dittmar G; Scheidereit C
Mol Cell; 2010 Oct; 40(1):63-74. PubMed ID: 20932475
[TBL] [Abstract][Full Text] [Related]
51. Overexpression of heme oxygenase-1 induced by constitutively activated NF-κB as a potential therapeutic target for activated B-cell-like diffuse large B-cell lymphoma.
Huang J; Guo P; Ma D; Lin X; Fang Q; Wang J
Int J Oncol; 2016 Jul; 49(1):253-64. PubMed ID: 27211510
[TBL] [Abstract][Full Text] [Related]
52. Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with Abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukemia cells.
Okabe S; Tauchi T; Tanaka Y; Sakuta J; Ohyashiki K
Oncotarget; 2015 Aug; 6(24):20231-40. PubMed ID: 26008977
[TBL] [Abstract][Full Text] [Related]
53. Identification of Ezrin-Radixin-Moesin proteins as novel regulators of pathogenic B-cell receptor signaling and tumor growth in diffuse large B-cell lymphoma.
Pore D; Bodo J; Danda A; Yan D; Phillips JG; Lindner D; Hill BT; Smith MR; Hsi ED; Gupta N
Leukemia; 2015 Sep; 29(9):1857-67. PubMed ID: 25801911
[TBL] [Abstract][Full Text] [Related]
54. Annexin A5 inhibits diffuse large B-cell lymphoma cell invasion and chemoresistance through phosphatidylinositol 3-kinase signaling.
Wang J; Zhang Y; Liu X; Ma J; Liu P; Hu C; Zhang G
Oncol Rep; 2014 Dec; 32(6):2557-63. PubMed ID: 25323007
[TBL] [Abstract][Full Text] [Related]
55. Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma.
Dupont T; Yang SN; Patel J; Hatzi K; Malik A; Tam W; Martin P; Leonard J; Melnick A; Cerchietti L
Oncotarget; 2016 Jan; 7(3):3520-32. PubMed ID: 26657288
[TBL] [Abstract][Full Text] [Related]
56. PF-04691502, a dual PI3K/mTOR inhibitor has potent pre-clinical activity by inducing apoptosis and G1 cell cycle arrest in aggressive B-cell non-Hodgkin lymphomas.
Chen D; Mao C; Zhou Y; Su Y; Liu S; Qi WQ
Int J Oncol; 2016 Jan; 48(1):253-60. PubMed ID: 26549638
[TBL] [Abstract][Full Text] [Related]
57. siRNA-induced TRAF6 knockdown promotes the apoptosis and inhibits the invasion of human lung cancer SPC-A1 cells.
He Z; Huang C; Lin G; Ye Y
Oncol Rep; 2016 Apr; 35(4):1933-40. PubMed ID: 26847475
[TBL] [Abstract][Full Text] [Related]
58. The clinical significance of Mda-7/IL-24 and C-myb expression in tumor tissues of patients with diffuse large B cell lymphoma.
Ma M; Zhao R; Yang X; Zhao L; Liu L; Zhang C; Wang X; Shan B
Exp Ther Med; 2018 Aug; 16(2):649-656. PubMed ID: 30112030
[TBL] [Abstract][Full Text] [Related]
59. microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb.
Zhang J; Luo N; Luo Y; Peng Z; Zhang T; Li S
Int J Oncol; 2012 Mar; 40(3):747-56. PubMed ID: 22025269
[TBL] [Abstract][Full Text] [Related]
60. The Cellular Distribution of RanGAP1 Is Regulated by CRM1-Mediated Nuclear Export in Mammalian Cells.
Cha K; Sen P; Raghunayakula S; Zhang XD
PLoS One; 2015; 10(10):e0141309. PubMed ID: 26506250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
